Merck to Acquire ArQule for $2.7B

 Merck to Acquire ArQule for $2.7B

Merck to Acquire ArQule for $2.7B

Shots:

  • Merck to acquire Arqule in all-cash transactions at $20/share, making a total deal value $2.7B. The transaction is expected to be completed in Q1’20
  • The focus of the acquisition is to bolster Merck’s oncology pipeline with the addition of ArQule’s lead investigational candidate, ARQ 531, a precision therapy to treat hematological malignancies
  • ArQule’s ARQ 531 (PO) is a novel BTK inhibitor, currently being evaluated in P-II dose-expansion study for the treatment of B-cell malignancies and has demonstrated safety and anti-tumor activity for the treatment of patients with r/r CLL and Richter’s Transformation in its early studies

Click here to­ read full press release/ article | Ref: Merck | Image: ArQule

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post